Harmony Biosciences has reported the acquisition of Epygenix Therapeutics to expand its late-stage CNS pipeline by adding rare epilepsy franchise
The acquisition brings clemizole hydrochloride (EPX-100), under a registrational study for Dravet syndrome (topline data anticipated in 2026) and is scheduled to enter a P-III study for Lennox-Gastaut syndrome in H2’24, along with EPX-200, undergoing IND-enabling studies, into Harmony’s pipeline
Under the agreement, Epygenix received $35M in cash with a potential of receiving ~$130M as development & regulatory milestones plus additional ~$515M as sales-based milestones
Ref: Harmony Biosciences | Image: Harmony Biosciences
Related News:- Harmony Biosciences Collaborates with Bioprojet to Develop TPM-1116 as a Treatment of Narcolepsy and Other Sleep/Wake Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
